BioStock: Curasight takes the next step in the two new indications

So far, 2022 has been a rather decisive year for Copenhagen based Curasight. After adding head and neck cancer and neuroendocrine tumours to the list of focus indications for drug candidate uTRACE, the time has now come to pursue them also for uTREAT. The company announced recently the start of preclinical studies in both the indications, further building on its theranostic strategy.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/10/curasight-takes-the-next-step-in-the-two-new-indications/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se